OncoPSMA GlyPro MMAE
Alternative Names: OncoPSMA-GlyPro-MMAELatest Information Update: 25 Jul 2024
At a glance
- Originator Philochem
- Class Antineoplastics; Auristatins; Drug conjugates; Small molecules
- Mechanism of Action Apoptosis inhibitors; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Prostate cancer
Most Recent Events
- 25 Jul 2024 Pharmacodynamics data from a preclinical studies in Cancer released by Philochem (Philochem, July 2024)
- 25 Jul 2024 Philochem plans a clinical trial for prostate cancer in 2025 (Philochem pipeline, July 2024)
- 19 Jan 2024 Preclinical development in Prostate cancer in Switzerland (Parenteral) (Philochem pipeline, January 2023)